81 related articles for article (PubMed ID: 2695084)
1. A spontaneous sarcoma dependent on host tumor-specific immune lymphocytes.
Katz JD; Bonavida B
Bioessays; 1989 Dec; 11(6):181-5. PubMed ID: 2695084
[TBL] [Abstract][Full Text] [Related]
2. The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy.
Katz JD; Lebow LT; Bonavida B
J Immunol; 1989 Aug; 143(4):1387-95. PubMed ID: 2663994
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
Ohnishi K; Bonavida B
J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
[TBL] [Abstract][Full Text] [Related]
4. Serological demonstration of an allogeneic Ia.7 antigen on the cell surface of SJL/J-derived reticulum cell sarcomas.
Wilbur SM; Marelli O; Bonavida B
Cancer Res; 1983 Sep; 43(9):4266-70. PubMed ID: 6347368
[TBL] [Abstract][Full Text] [Related]
5. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
6. Specific lymphocyte-target cell conjugate formation between tumor-specific helper T-cell hybridomas and IA-bearing RCS tumors and IE-bearing allogeneic cells. I. Role of Ia and both L3T4 and LFA-1 antigens in recognition/binding.
Ohnishi K; Bonavida B
J Immunol; 1986 Dec; 137(11):3681-8. PubMed ID: 2946766
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate alloantigen-like specificities detected on reticulum cell sarcomas of SJL/J mice: characterization and biologic role.
Bonavida B; Roman JM; Hutchinson IV
Transplant Proc; 1980 Mar; 12(1):59-64. PubMed ID: 6154360
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of IA positive reticulum cell sarcoma tumor cell growth in syngeneic SJL/J mice by passive administration of monoclonal anti-IA antibody.
Sakano T; Bonavida B
Cancer Res; 1986 Jul; 46(7):3245-8. PubMed ID: 3518916
[TBL] [Abstract][Full Text] [Related]
9. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
10. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
11. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
12. Regulation of reticulum cell sarcoma tumor growth in SJL/J mice by a serum inhibitor affecting T-cell proliferation.
Sakano T; Wilbur SM; Bonavida B
Cancer Res; 1985 Apr; 45(4):1573-8. PubMed ID: 3884142
[TBL] [Abstract][Full Text] [Related]
13. Ia-restricted interaction of normal lymphoid cells and SJL lymphoma (reticulum cell sarcoma) leading to lymphokine production. II. Rapid production of antibody-enhancing factor, interleukin 2, and immune interferon.
Ponzio NM; Hayama T; Nagler C; Katz IR; Hoffmann MK; Gilbert K; Vilcek J; Thorbecke GJ
J Natl Cancer Inst; 1984 Feb; 72(2):311-20. PubMed ID: 6420599
[TBL] [Abstract][Full Text] [Related]
14. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
15. Characterization and growth factor requirements of SJL lymphomas. I. Development of a B cell growth factor-dependent in vitro cell line, cRCS-X.
Lasky JL; Ponzio NM; Thorbecke GJ
J Immunol; 1988 Jan; 140(2):679-87. PubMed ID: 3275720
[TBL] [Abstract][Full Text] [Related]
16. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
19. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
Russell PS; Chase CM; Burton RC
J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
